Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue

Among metabolic diseases, carbohydrate metabolism disorders are the most widespread. The most common glucose pathological conditions are acquired and may increase the risk of type 2 diabetes, obesity, heart diseases, stroke, and kidney insufficiency. Phosphodiesterase type 5 inhibitors (PDE5i) have...

Full description

Saved in:
Bibliographic Details
Published in:International journal of endocrinology 2020, Vol.2020 (2020), p.1-8
Main Authors: Antinozzi, Cristina, Di Luigi, Luigi, Sgrò, Paolo
Format: Article
Language:English
Subjects:
Adipocytes
Avanafil
Carbohydrate metabolism
Cardiovascular disease
Dextrose
Diabetes
Diabetes therapy
Drug therapy
Endocrinology
Endothelium
Enzymes
Erectile dysfunction
Gene expression
Glucose
Glucose metabolism
Health aspects
Heart diseases
Hypertension
Impotence
Insulin
Insulin resistance
Kinases
Metabolic disorders
Musculoskeletal system
Nitric oxide
Obesity
Physiological aspects
Proteins
Review
Smooth muscle
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Among metabolic diseases, carbohydrate metabolism disorders are the most widespread. The most common glucose pathological conditions are acquired and may increase the risk of type 2 diabetes, obesity, heart diseases, stroke, and kidney insufficiency. Phosphodiesterase type 5 inhibitors (PDE5i) have long been used as an effective therapeutic option for the treatment of erectile dysfunction (ED). Different studies have demonstrated that PDE5i, by sensitizing insulin target tissues to insulin, play an important role in controlling the action of insulin and glucose metabolism, highlighting the protective action of these drugs against metabolic diseases. In this review, we report the latest knowledge about the role of PDE5i in the metabolic diseases of insulin resistance and type 2 diabetes, highlighting clinical aspects and potential treatment approaches. Although various encouraging data are available, further in vivo and in vitro studies are required to elucidate the mechanism of action and their clinical application in humans.
ISSN:1687-8337
1687-8345
DOI:10.1155/2020/7078108